# One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)

> **NCT00246467** · PHASE1 · COMPLETED · sponsor: **PharmAthene UK Limited** · enrollment: 123 (actual)

## Conditions studied

- Plague

## Interventions

- **BIOLOGICAL:** Alhydrogel
- **BIOLOGICAL:** rF1 and rV protein antigens

## Key facts

- **NCT ID:** NCT00246467
- **Lead sponsor:** PharmAthene UK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2008-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246467, "One Year Study to Evaluate Three Different Adjuvanted Doses of the Recombinant Plague Vaccine (rF1 and rV Antigens)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00246467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*